ER/HER2/Ki67 Breast Cancer Subtypes as Predictive Factors for Response to Adjuvant Dose-dense Therapy, and Basal Subtypes of Double-negative Breast Cancer as Prognostic Factors in Intergroup Trial C9741
- To identify biomarkers that can be used to individually tailor the use of adjuvant
dose-dense therapy in women with stage II or IIIA breast cancer.
- To identify groups of patients who have a poor prognosis despite adjuvant chemotherapy
and who should be prospectively targeted for new approaches to adjuvant treatment.
OUTLINE: This is a multicenter study.
Tissue samples are collected from patients. Tissue samples are analyzed by
immunohistochemistry (Ki67, CK5/6, EGFR, ER) and fluorescence in situ hybridization (FISH).
Matthew J. Ellis, MD, PhD, FRCP
Washington University Siteman Cancer Center
United States: Federal Government